Investment Summary |
|
|---|---|
| Date | 2014-05-15 |
| Target | Meituan |
| Sector | Information Technology |
| Investor(s) |
General Atlantic
Ascendent Capital Partners |
| Deal Type | Growth Capital |
SEARCH BY
| Category | Growth Capital Firm |
|---|---|
| Founded | 1980 |
| PE ASSETS | 105.0B USD |
| Size | Mega |
| Type | Sector Agnostic |
General Atlantic is a large private equity firm that invests globally in growth-oriented public and private companies. Broad areas of interest include financial services, media and consumer, healthcare, enterprise solutions, communications and electronics, and energy. General Atlantic looks to invest $40 to $400 million in transactions that support growth, expansions, buy-outs, consolidations and build-ups. General Atlantic seeks to make 8 to 12 investments per year with an investment horizon of five to ten years. The Firm's geographic coverage spans North America; Europe; Asia/Pacific; and India. General Atlantic was formed in 1980 and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 132 of 364 |
| Sector: Information Technology M&A | 22 of 45 |
| Type: Growth Capital M&A Deals | 54 of 139 |
| Country: China M&A | 12 of 33 |
| Year: 2014 M&A | 10 of 18 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-05-09 |
Jumei
Beijing, China Jumei is an online retailer of beauty products, providing high-demand branded products to young, urban female customers through merchandise and marketplace sales models. Jumei was founded in 2009 and is based in Beijing, China. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-05-27 |
Aperture Group
Chicago, Illinois, United States Aperture Group LLC (OptionsHouse) is a provider of online brokerage services. |
Buy | - |
Ascendent Capital Partners is a private equity firm focused on acquiring and investing in China-related companies. The Firm looks to leverage its network and experience when working with and helping companies grow. Ascendant Capital Partners has offices in Shanghai and Hong Kong.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 4 |
| Sector: Information Technology M&A | 1 of 2 |
| Type: Growth Capital M&A Deals | 1 of 2 |
| Country: China M&A | 1 of 4 |
| Year: 2014 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-06-08 |
SciClone Pharmaceuticals
Shanghai, China SciClone Pharmaceuticals is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as an immune system enhancer, according to the local regulatory approvals. SciClone Pharmaceuticals was founded in 1989 and is based in Shanghai, China. |
Buy | $605M |
